PFE - Cabaletta Bio Aims For $87 Million IPO
Quick Take
Cabaletta Bio (CABA) has filed to raise $87 million in an IPO of its common stock, according to an S-1/A registration statement.
The firm is developing drug treatments for Pemphigus and other autoimmune conditions.
CABA is an ultra-high-risk pre-Phase 1 stage biopharma, and the IPO is likely more suited for very long-term hold institutional investors.
Company & Technology
Philadelphia-based Cabaletta was founded to advance treatments for various autoimmune diseases.
Management is headed by President and Chief Executive Officer Steven Nichtberger, M.D., who has been with the firm since inception and